Evaluation of electrochemotherapy in the management of anal sac apocrine gland adenocarcinomas in dogs: a retrospective study
Paola Valenti ,Francesco Menicagli,Alfonso Baldi,Gabriele Barella,Chiara Catalucci,Valeria Attorri,Enrico Paolo Spugnini.
|Cited by 8 Articles|
Background: Electrochemotherapy (ECT) combines the administration of anticancer drugs with the delivery of electric pulses, thus increasing the drug uptake through the cell membranes, resulting in increased efficacy.
Aim: The aim of our study was to describe the tolerability and efficacy of ECT for the treatment of Apocrine Gland Anal Sac Adenocarcinoma (AGASAC).
Methods: Medical records of dogs with a diagnosis of AGASAC that were treated with ECT were retrospectively evaluated.
Each dog received 20 mg/m2 of bleomycin intravenously. Based on clinician decision, the primary tumor or tumor bed was also infiltrated with cisplatin at the dose of 0.5 mg/cm2.
Trains of permeabilizing biphasic electric pulses were then applied under general anesthesia.
Results: Ten dogs were enrolled in the study.
Six dogs (60 %) had partial response (PR), 3 dogs (30 %) had stable disease (SD) and one dog treated for microscopic disease did not show any sign of local relapse 305 days after treatment, being still alive and in complete remission (CR) at the time of writing.
Median time to progression was 303 days and median survival time was 365 days.
The treatment was well tolerated and local side effects were minimal. No systemic effects were documented.
Conclusion: This preliminary study suggests that ECT may be beneficial for dogs with AGASAC and could be a useful addition to the current therapeutic options in consideration of its low cost, limited toxicity and ease of administration.
Key words: Anal Gland Anal Sac Adenocarcinoma, Bleomycin, Cisplatin, Dog, Electrochemotherapy